Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients

BACKGROUND: Suppressor of cytokine signaling (SOCS) 1 and 3 methylation have been associated with clinical features and outcomes of cancer patients. However, their roles in determining the treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) re...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Bei-Ge, Wang, Neng, Huang, Jian, Yang, Yuan, Sun, Liang-Liang, Pan, Ze-Ya, Zhou, Wei-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438677/
https://www.ncbi.nlm.nih.gov/pubmed/28404963
http://dx.doi.org/10.18632/oncotarget.16157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438677/
https://www.ncbi.nlm.nih.gov/pubmed/28404963
http://dx.doi.org/10.18632/oncotarget.16157

Ejemplares similares